12:00 AM
Sep 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

BIOD-123: Phase II started

Biodel began an open-label, U.S. Phase II trial to compare BIOD-123 plus Lantus insulin glargine vs. insulin lispro plus Lantus...

Read the full 89 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >